New Risk • May 05
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 94% Dividend per share is over 29x cash flows per share. Dividend yield: 2.1% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Apr 30
Full year 2025 earnings released: EPS: CN¥3.58 (vs CN¥4.93 in FY 2024) Full year 2025 results: EPS: CN¥3.58 (down from CN¥4.93 in FY 2024). Revenue: CN¥9.00b (down 17% from FY 2024). Net income: CN¥2.16b (down 28% from FY 2024). Profit margin: 24% (down from 28% in FY 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Price Target Changed • Apr 21
Price target decreased by 7.2% to CN¥211 Down from CN¥227, the current price target is an average from 7 analysts. New target price is 46% above last closing price of CN¥144. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥4.24 for next year compared to CN¥4.93 last year. Tillkännagivande • Mar 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2026 Results on Apr 30, 2026 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q1, 2026 results on Apr 30, 2026 Tillkännagivande • Dec 26
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2025 Results on Apr 30, 2026 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report fiscal year 2025 results on Apr 30, 2026 Reported Earnings • Oct 19
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥1.14 (down from CN¥1.60 in 3Q 2024). Revenue: CN¥2.06b (down 26% from 3Q 2024). Net income: CN¥687.0m (down 29% from 3Q 2024). Profit margin: 33% (down from 35% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2025 Results on Oct 18, 2025 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q3, 2025 results on Oct 18, 2025 Reported Earnings • Aug 23
Second quarter 2025 earnings released: EPS: CN¥0.73 (vs CN¥1.23 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.73 (down from CN¥1.23 in 2Q 2024). Revenue: CN¥2.24b (down 9.8% from 2Q 2024). Net income: CN¥442.5m (down 41% from 2Q 2024). Profit margin: 20% (down from 30% in 2Q 2024). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • Jun 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2025 Results on Aug 30, 2025 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report first half, 2025 results on Aug 30, 2025 Tillkännagivande • Jun 24
Zhangzhou Pientzehuang Pharmaceutical., Ltd(SHSE:600436) dropped from Shanghai Stock Exchange 180 Value Index Zhangzhou Pientzehuang Pharmaceutical.Ltd has been removed from Shanghai Stock Exchange 180 Value Index . Tillkännagivande • May 29
Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, Jun 20, 2025 Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, Jun 20, 2025, at 09:00 China Standard Time. Location: 2F, Xiangjiang Hotel, Xiangcheng District, Zhangzhou, Fujian China Reported Earnings • Apr 27
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥4.93 (up from CN¥4.64 in FY 2023). Revenue: CN¥10.8b (up 7.3% from FY 2023). Net income: CN¥2.98b (up 6.4% from FY 2023). Profit margin: 28% (in line with FY 2023). Revenue missed analyst estimates by 3.9%. Earnings per share (EPS) also missed analyst estimates by 5.7%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 28
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2025 Results on Apr 30, 2025 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q1, 2025 results on Apr 30, 2025 Buy Or Sell Opportunity • Feb 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to CN¥201. The fair value is estimated to be CN¥253, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 8.5%. Revenue is forecast to grow by 26% in 2 years. Earnings are forecast to grow by 31% in the next 2 years. Board Change • Jan 09
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Zhengda Tian was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buy Or Sell Opportunity • Jan 02
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to CN¥209. The fair value is estimated to be CN¥268, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 8.5%. Revenue is forecast to grow by 28% in 2 years. Earnings are forecast to grow by 36% in the next 2 years. Tillkännagivande • Dec 27
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2024 Results on Apr 26, 2025 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 19
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: CN¥1.60 (up from CN¥1.44 in 3Q 2023). Revenue: CN¥2.80b (up 9.6% from 3Q 2023). Net income: CN¥965.1m (up 12% from 3Q 2023). Profit margin: 35% (in line with 3Q 2023). Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥230, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥231 per share. Tillkännagivande • Sep 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2024 Results on Oct 19, 2024 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q3, 2024 results on Oct 19, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥235, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥231 per share. New Risk • Aug 17
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 125% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Dividend is not well covered by cash flows (125% cash payout ratio). Tillkännagivande • Aug 12
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire Zhangzhou Mingyuan Spice Co., Ltd. from Zhangzhou State-owned Asset Investment Management Co., Ltd. for approximately CNY 250 million. Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire Zhangzhou Mingyuan Spice Co., Ltd. from Zhangzhou State-owned Asset Investment Management Co., Ltd. for approximately CNY 250 million on August 9, 2024. A cash consideration of CNY 254.15 million will be paid by Zhangzhou Pientzehuang Pharmaceutical., Ltd. As part of consideration, CNY 254.15 million is paid towards common equity of Zhangzhou Mingyuan Spice Co., Ltd. The fund will be raised from equity.
For the period ending March 31, 2024, Zhangzhou Mingyuan Spice Co., Ltd. reported total assets of CNY 184.5 million and total common equity of CNY 142.5 million.
The transaction is subject to approval of offer by acquirer board. The deal has been approved by the board. Reported Earnings • Jul 25
Second quarter 2024 earnings released: EPS: CN¥1.23 (vs CN¥1.27 in 2Q 2023) Second quarter 2024 results: EPS: CN¥1.23 (down from CN¥1.27 in 2Q 2023). Revenue: CN¥2.48b (up 2.6% from 2Q 2023). Net income: CN¥745.2m (down 3.4% from 2Q 2023). Profit margin: 30% (down from 32% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Tillkännagivande • Jun 28
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2024 Results on Aug 17, 2024 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report first half, 2024 results on Aug 17, 2024 Tillkännagivande • Apr 21
Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024 Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024, at 09:00 China Standard Time. Reported Earnings • Apr 20
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: EPS: CN¥1.62 (up from CN¥1.28 in 1Q 2023). Revenue: CN¥3.17b (up 21% from 1Q 2023). Net income: CN¥974.5m (up 27% from 1Q 2023). Profit margin: 31% (up from 29% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) also surpassed analyst estimates by 2.2%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 29
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2024 Results on Apr 20, 2024 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q1, 2024 results on Apr 20, 2024 Reported Earnings • Jan 31
Full year 2023 earnings released: EPS: CN¥4.61 (vs CN¥4.10 in FY 2022) Full year 2023 results: EPS: CN¥4.61 (up from CN¥4.10 in FY 2022). Revenue: CN¥10.0b (up 15% from FY 2022). Net income: CN¥2.78b (up 13% from FY 2022). Profit margin: 28% (in line with FY 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Buying Opportunity • Jan 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be CN¥288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 36% in 2 years. Earnings is forecast to grow by 48% in the next 2 years. Tillkännagivande • Dec 29
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report fiscal year 2023 results on Apr 20, 2024 Reported Earnings • Oct 18
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Third quarter 2023 results: EPS: CN¥1.44 (up from CN¥1.22 in 3Q 2022). Revenue: CN¥2.55b (up 17% from 3Q 2022). Net income: CN¥863.8m (up 17% from 3Q 2022). Profit margin: 34% (in line with 3Q 2022). Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) also missed analyst estimates by 3.0%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Sep 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2023 Results on Oct 21, 2023 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 21, 2023 Reported Earnings • Aug 19
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: CN¥1.27 (up from CN¥1.04 in 2Q 2022). Revenue: CN¥2.42b (up 17% from 2Q 2022). Net income: CN¥771.2m (up 23% from 2Q 2022). Profit margin: 32% (up from 30% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 4.3%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 15
Second quarter 2023 earnings released: EPS: CN¥1.26 (vs CN¥1.04 in 2Q 2022) Second quarter 2023 results: EPS: CN¥1.26 (up from CN¥1.04 in 2Q 2022). Revenue: CN¥2.42b (up 17% from 2Q 2022). Net income: CN¥760.6m (up 22% from 2Q 2022). Profit margin: 32% (up from 30% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 15% per year. Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥313, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 113% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥170 per share. Reported Earnings • Apr 16
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2023 results: EPS: CN¥1.28 (up from CN¥1.14 in 1Q 2022). Revenue: CN¥2.63b (up 12% from 1Q 2022). Net income: CN¥769.7m (up 12% from 1Q 2022). Profit margin: 29% (in line with 1Q 2022). Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) exceeded analyst estimates by 10%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Mar 28
Price target decreased by 8.1% to CN¥302 Down from CN¥329, the current price target is an average from 7 analysts. New target price is 8.4% above last closing price of CN¥279. Stock is down 9.7% over the past year. The company is forecast to post earnings per share of CN¥5.31 for next year compared to CN¥4.09 last year. Reported Earnings • Feb 01
Full year 2022 earnings released: EPS: CN¥4.09 (vs CN¥4.03 in FY 2021) Full year 2022 results: EPS: CN¥4.09 (up from CN¥4.03 in FY 2021). Revenue: CN¥8.69b (up 8.4% from FY 2021). Net income: CN¥2.47b (up 1.5% from FY 2021). Profit margin: 28% (down from 30% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhi Peng Fan was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Oct 26
Price target decreased to CN¥331 Down from CN¥359, the current price target is an average from 8 analysts. New target price is 41% above last closing price of CN¥235. Stock is down 43% over the past year. The company is forecast to post earnings per share of CN¥4.33 for next year compared to CN¥4.03 last year. Buying Opportunity • Oct 25
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 25%. The fair value is estimated to be CN¥288, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. Revenue is forecast to grow by 37% in 2 years. Earnings is forecast to grow by 57% in the next 2 years. Reported Earnings • Oct 23
Third quarter 2022 earnings released: EPS: CN¥1.22 (vs CN¥1.48 in 3Q 2021) Third quarter 2022 results: EPS: CN¥1.22 (down from CN¥1.48 in 3Q 2021). Revenue: CN¥2.19b (down 3.1% from 3Q 2021). Net income: CN¥738.1m (down 18% from 3Q 2021). Profit margin: 34% (down from 40% in 3Q 2021). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth. Buying Opportunity • Sep 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 26%. The fair value is estimated to be CN¥319, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 27%. Revenue is forecast to grow by 36% in 2 years. Earnings is forecast to grow by 49% in the next 2 years. Price Target Changed • Aug 24
Price target increased to CN¥380 Up from CN¥355, the current price target is an average from 7 analysts. New target price is 31% above last closing price of CN¥290. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥4.84 for next year compared to CN¥4.03 last year. Price Target Changed • Jun 25
Price target decreased to CN¥389 Down from CN¥438, the current price target is an average from 8 analysts. New target price is 14% above last closing price of CN¥342. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥4.98 for next year compared to CN¥4.03 last year. Price Target Changed • Jun 02
Price target decreased to CN¥389 Down from CN¥438, the current price target is an average from 8 analysts. New target price is 29% above last closing price of CN¥301. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥4.98 for next year compared to CN¥4.03 last year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: CN¥1.14 (up from CN¥0.94 in 1Q 2021). Revenue: CN¥2.35b (up 17% from 1Q 2021). Net income: CN¥689.3m (up 22% from 1Q 2021). Profit margin: 29% (up from 28% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.6%. Over the next year, revenue is forecast to grow 19%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Zhi Peng Fan was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 17
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: CN¥4.03 (up from CN¥2.77 in FY 2020). Revenue: CN¥8.02b (up 23% from FY 2020). Net income: CN¥2.43b (up 46% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.6%. Over the next year, revenue is forecast to grow 18%, compared to a 27% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Mar 22
Price target decreased to CN¥460 Down from CN¥516, the current price target is an average from 6 analysts. New target price is 49% above last closing price of CN¥308. Stock is up 17% over the past year. The company is forecast to post earnings per share of CN¥4.11 for next year compared to CN¥2.77 last year. Buying Opportunity • Mar 07
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 33%. The fair value is estimated to be CN¥394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% per annum over the last 3 years. Earnings per share has grown by 23% per annum over the last 3 years. Price Target Changed • Oct 19
Price target increased to CN¥435 Up from CN¥406, the current price target is an average from 6 analysts. New target price is approximately in line with last closing price of CN¥439. Stock is up 79% over the past year. The company is forecast to post earnings per share of CN¥3.67 for next year compared to CN¥2.77 last year. Reported Earnings • Oct 16
Third quarter 2021 earnings released: EPS CN¥1.48 (vs CN¥0.77 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.26b (up 24% from 3Q 2020). Net income: CN¥896.2m (up 93% from 3Q 2020). Profit margin: 40% (up from 26% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 73% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 22
Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.85b (up 21% from 2Q 2020). Net income: CN¥549.9m (up 39% from 2Q 2020). Profit margin: 30% (up from 26% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥1.85b (up 21% from 2Q 2020). Net income: CN¥549.0m (up 38% from 2Q 2020). Profit margin: 30% (up from 26% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Apr 28
Price target increased to CN¥281 Up from CN¥259, the current price target is an average from 6 analysts. New target price is 18% below last closing price of CN¥345. Stock is up 142% over the past year. Reported Earnings • Apr 26
First quarter 2021 earnings released: EPS CN¥0.94 (vs CN¥0.78 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥2.00b (up 17% from 1Q 2020). Net income: CN¥565.3m (up 21% from 1Q 2020). Profit margin: 28% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Feb 19
Price target raised to CN¥315 Up from CN¥277, the current price target is an average from 6 analysts. The new target price is 18% below the current share price of CN¥383. As of last close, the stock is up 199% over the past year. Is New 90 Day High Low • Feb 02
New 90-day high: CN¥326 The company is up 42% from its price of CN¥229 on 04 November 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥213 per share. Analyst Estimate Surprise Post Earnings • Jan 23
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 28%, compared to a 186% growth forecast for the Pharmaceuticals industry in China. Reported Earnings • Jan 20
Full year 2020 earnings released: EPS CN¥2.76 The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥6.51b (up 14% from FY 2019). Net income: CN¥1.67b (up 21% from FY 2019). Profit margin: 26% (up from 24% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 07
New 90-day high: CN¥300 The company is up 22% from its price of CN¥246 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥213 per share. Price Target Changed • Dec 22
Price target raised to CN¥269 Up from CN¥228, the current price target is an average from 8 analysts. The new target price is 9.8% above the current share price of CN¥245. As of last close, the stock is up 135% over the past year. Is New 90 Day High Low • Dec 16
New 90-day high: CN¥252 The company is up 3.0% from its price of CN¥245 on 17 September 2020. The Chinese market is also up 3.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥188 per share. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥212 The company is down 6.0% from its price of CN¥227 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥158 per share. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.59b, up 20% from the prior year. Total revenue was CN¥6.45b over the last 12 months, up 17% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 25
Annual earnings released: Earnings beat expectations Earnings per share (EPS) surpassed analyst estimates by 13% at CN¥0.77. Revenue is forecast to grow 23% over the next year, compared to a 30% growth forecast for the Pharmaceuticals industry in China. Tillkännagivande • Oct 19
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2020 Results on Oct 24, 2020 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report Q3, 2020 results on Oct 24, 2020 Tillkännagivande • Jul 30
Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd. Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd. on July 25, 2020. In a related transaction, Zhangzhou Pientzehuang will also invest fresh capital in Longhui Pharmaceutical Co., Ltd. Zhangzhou Pientzehuang Pharmaceutical., Ltd will in total invest CNY 44.4759 million as a part of both the transactions. Post acquisition, Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd. will hold 33.32% and 15.68% and Zhangzhou Pientzehuang Pharmaceutical., Ltd will hold a 51% stake in Longhui Pharmaceutical Co., Ltd. Zhangzhou Pientzehuang will use its own funds for both the transactions. For the year ended December 31, 2020, Longhui Pharmaceutical Co., Ltd. reported total assets of CNY 43.7627 million, Negative total common equity of CNY 1.4151 million, EBIT of CNY 22.0487 million and Net loss of CNY 6.5468 million. Tillkännagivande • Jul 09
Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2020 Results on Aug 22, 2020 Zhangzhou Pientzehuang Pharmaceutical., Ltd announced that they will report first half, 2020 results on Aug 22, 2020